COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide Friday, January 7, 2022

DISCLAIMER: These Alllandscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these
landscape documents Phasedoes
1 not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).  While WHO takes reasonable steps to verify the accuracy of the
information presentedPhasein1/2
these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes),
 quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein.  WHO also disclaims any and all liability or responsibility whatsoever for any death,
Phase 2 loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
disability, injury, suffering,
Phase 2/3
Phase 3
Phase 4
Summary Information on Vaccine Products in Clinical Development

1. - Number of vaccines in clinical development 137

194 137

2. - Number of vaccines in pre-clinical development 194 Vaccines in clinical development 137

0 50 100 150 200 250 300 350
Vaccines in pre-clinical development 194
Vaccines in pre-clinical development Vaccines in clinical development

3. - Candidates in clinical phase 0% 5% 10% 15% 20% 25% 30% 35% 40%
PS Chart Title
Filter All Select phase of development (default is all)

Platform Candidate vaccines (no. and %) DNA

PS Protein subunit 47 35%
VVnr Viral Vector (non-replicating) 20 15% RNA
DNA DNA 15 11%
IV Inactivated Virus 18 13%
VLP
RNA RNA 23 17%
VVr Viral Vector (replicating) 2 1%
VLP Virus Like Particle 6 4% LAV
VVr + APC VVr + Antigen Presenting Cell 2 1%
LAV Live Attenuated Virus 2 1% BacAg-SpV
VVnr + APC VVnr + Antigen Presenting Cell 1 1%
BacAg-SpV Bacterial antigen-spore expression vector 1 1%
137

4. - Number of doses, schedule and route of administration of candidates in clinical phase

other not specified
Number of doses & schedule Candidate vaccines (no. and %) 23%
Day 0
1 dose 21 15% 1 dose 21 15%
Day 0 21 2 doses 83
2 doses 83 61% 3 doses 2
Day 0 + 14 7 other not s 31
Day 0 + 21 33
Day 0 + 28 43 Day 0 21
1 dose
3 doses 2 1% Day 0 + 14 7 Day 0 + 14
Day 0 + 28 + 56 2 Day 0 + 21 33 5%
TBD / No Data (ND) 31 23% Day 0 + 28 43
137 Day 0 + 28 + 56 Day 0 + 328doses 2
Route of administration 1% other not s 31
Oral 4 3%
Injectable 115 84%
SC Sub cutaneous 5 4%
ID Intra dermal 5 4% 2 doses
IM Intra muscular 105 77%
IN Intra nasal 8 6% Day 0 + 21
AE Aerosol 1 1% 24%
IH Inhaled 1 1%
TBD / No Data (ND) 18 13% Day 0 + 28
31%
Landscape of candidate vaccines in clinical development Friday, January 7, 2022
DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or
construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).  While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the
accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes),  quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein.  WHO also disclaims any and all liability or
responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

New information that has been added this week is highlighted in yellow
(NCT04510207) This Phase 3 trial assesses both the Wuhan and Beijing vaccine in the same study.
*Pending confirmation on the phase of study which is not specified in the registry.
** Trials that have indicated assessment of vaccine efficacy against SARS-COV-2 variants.
The informaion provided is taken directly from data available in the trial registries. In cases where the trial is registrered as N/A or without a defined clincial phase, it has been listed in the column "Phase not reported".
TBD (To be defined)
NR (Not Reported)

Information highlighted in red indicates a change in the development of the vaccine

Vaccine Number of
ID platform Vaccine platform description Type of candidate vaccine Schedule Route of administration Developers Phase
acronym doses

1 IV Inactivated virus CoronaVac; inactivated SARS-CoV-2 vaccine (vero cell) 2 Day 0 + 14 IM Sinovac Research and Development Co., Ltd Phase 4

2 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) 2 Day 0 + 21 IM Sinopharm; Phase 4
WIBP COVID-19 vaccine China National Biotec Group Co;
Wuhan Institute of Biological Products

3 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell), vaccine name BBIBP-CorV 2 Day 0 + 21 IM Sinopharm; Phase 4
China National Biotec Group Co;
Wuhan Institute of Biological Products
Beijing Institute of Biological Products

4 VVnr Viral vector (Non-replicating) ChAdOx1-S - (AZD1222) 1-2 Day 0 + 28 IM AstraZeneca + University of Oxford Phase 4
Covishield

Vaxzevria

1-2 Day 0 + 28 IN University of Oxford Phase 1

5 VVnr Viral vector (Non-replicating) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) 1 Day 0 IM CanSino Biological Inc./Beijing Institute of Biotechnology Phase 4
Ad5-nCoV

6 VVnr Viral vector (Non-replicating) Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH) 1 Day 0 IH CanSino Biological Inc./Beijing Institute of Biotechnology Phase 3

7 VVnr Viral vector (Non-replicating) Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) 2 Day 0 + 21 IM Gamaleya Research Institute ; Health Ministry of the Russian Federation Phase 3
Sputnik V COVID-19 vaccine

8 VVnr Viral vector (Non-replicating) Ad26.COV2.S 1-2 Day 0 or Day 0 +56 IM Janssen Pharmaceutical Phase 4
Johnson & Johnson

9 PS Protein subunit SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 2 Day 0 + 21 IM Novavax Phase 3
glycoprotein nanoparticle vaccine adjuvanted with Matrix M) NVX-CoV2373

10 RNA RNA based vaccine mRNA-1273 2 Day 0 + 28 IM Moderna + National Institute of Allergy and Infectious Diseases (NIAID) Phase 4

11 RNA RNA based vaccine BNT162b2 (3 LNP-mRNAs ), also known as "Comirnaty" 2 Day 0 + 21 IM Pfizer/BioNTech + Fosun Pharma Phase 4

12 PS Protein subunit Recombinant SARS-CoV-2 vaccine (CHO Cell) 2-3 Day 0 + 28 or IM Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Phase 3
Chinese Academy of Sciences
Day 0 + 28 + 56 Zhongyianke Biotech
Liaoning Maokangyuan Biotech
12

Academy of Military Medical Sciences

13 RNA RNA based vaccine CVnCoV Vaccine 2 Day 0 + 28 IM CureVac AG Phase 3

14 IV Inactivated virus SARS-CoV-2 vaccine (vero cells) 2 Day 0 + 28 IM Institute of Medical Biology + Chinese Academy of Medical Sciences Phase 3

15 IV Inactivated virus QazCovid-in® - COVID-19 inactivated vaccine 2 Day 0 + 21 IM Research Institute for Biological Safety Problems, Rep of Kazakhstan Phase 3

16 Inovio Pharmaceuticals + International Vaccine Institute + Advaccine

DNA DNA based vaccine INO-4800+electroporation  2 Day 0 + 28 ID Phase 3
(Suzhou) Biopharmaceutical Co., Ltd

17 DNA DNA based vaccine AG0301-COVID19 2 Day 0 + 14 IM AnGes + Takara Bio + Osaka University Phase 2/3

18 DNA DNA based vaccine nCov vaccine 3 Day 0 + 28 + 56 ID Zydus Cadila Phase 3

19 DNA DNA based vaccine GX-19N 2 Day 0 + 28 IM Genexine Consortium Phase 2/3

20 IV Inactivated virus BBV152 vaccine 2 Day 0 + 14 IM Bharat Biotech International Limited Phase 3

21 PS Protein subunit KBP-COVID-19 (RBD-based) 2 Day 0 + 21 IM Kentucky Bioprocessing Inc. Phase 1/2
22 PS Protein subunit VAT00008: SARS-CoV-2 S protein with adjuvant 2 Day 0 + 21 IM Sanofi Pasteur + GSK Phase 3
(1) CoV2 preS dTM monovalent D614 antigen
(2) Bivalent (2-antigen) vaccine comprising spike protein of D614 and spike protein of the
SARS-CoV-2 Beta variant (B.1.351)
23 RNA RNA based vaccine ARCT-021  NR NR IM Arcturus Therapeutics Phase 2

24 VLP Virus like particle RBD SARS-CoV-2 HBsAg VLP vaccine 2 Day 0 + 28 IM Serum Institute of India + Accelagen Pty + SpyBiotech Phase 1/2

25 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) 2 Day 0 + 28 IM Shenzhen Kangtai Biological Products Co., Ltd. Phase 3

26 VVnr Viral vector (Non-replicating) GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S) 1 Day 0 IM ReiThera + Leukocare + Univercells Phase 2/3
27
VVnr Viral vector (Non-replicating) VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform 2 Day 0 + 28 Oral Vaxart Phase 2

28 VVnr Viral vector (Non-replicating) MVA-SARS-2-S 2 Day 0 + 28 IM University of Munich (Ludwig-Maximilians) Phase 1
29 PS Protein subunit CpG 1018/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) 2 Day 0 + 21 IM Clover Biopharmaceuticals Inc./Dynavax Phase 3

30 PS Protein subunit COVAX-19® Recombinant spike protein + adjuvant 2 Day 0 + 21 IM Vaxine Pty Ltd./CinnaGen Co. Phase 3
SPIKOGEN®

Protein subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 2 Day 0 + 28 IM CSL Ltd. + Seqirus + University of Queensland Phase 2/3

31 PS Protein subunit MVC-COV1901 (Spike-2P protein + adjuvant CpG 1018) 2 Day 0 + 28 IM Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Phase 4
Infectious Diseases (NIAID)

32 PS Protein subunit FINLAY-FR1 anti-SARS-CoV-2 Vaccine (RBD + adjuvant) 2 Day 0 + 28 IM Instituto Finlay de Vacunas Phase 2

33 PS Protein subunit FINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant) 2 Day 0 + 28 IM Instituto Finlay de Vacunas Phase 3

34 PS Protein subunit EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) 2 Day 0 + 21 IM Federal Budgetary Research Institution State Research Center of Virology Phase 3
and Biotechnology "Vector"

35 PS Protein subunit RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell) 2 Day 0 + 28 IM West China Hospital + Sichuan University Phase 3
WestVac Biopharma Co., Ltd.
35

36 PS Protein subunit IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) 1 Day 0 SC University Hospital Tuebingen Phase 1/2
37 PS Protein subunit UB-612 (Multitope peptide based S1-RBD-protein based vaccine) 2 Day 0 + 28 IM Vaxxinity Phase 2/3

Viral vector (Replicating) V591-001 - Measles-vector based (TMV-o38) 1-2 Day 0 + 28 IM Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + University of Phase 1/2
Pittsburgh

38 VVr Viral vector (Replicating) DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD ) 2 Day 0 + 28 IN University of Hong Kong, Xiamen University and Beijing Wantai Biological
Pharmacy Phase 3

39 RNA RNA based vaccine LNP-nCoVsaRNA 2 NR IM Imperial College London Phase 1

40 RNA RNA based vaccine SARS-CoV-2 mRNA vaccine (ARCoV) 2 Day 0 + 14 or IM Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Phase 3
Day 0 + 28 Abogen Biosciences

41 VLP Virus like particle Coronavirus-Like Particle COVID-19 (CoVLP) 2 Day 0 + 21 IM Medicago Inc. Phase 3
MT-2766
Other Name: CoVLP, AS03 adjuvant
42 VVr + APC Viral vector (Replicating) + APC Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with 3 Day 0 + 14 + 28 SC Shenzhen Geno-Immune Medical Institute Phase 1
immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs).

43 VVnr + APC Viral vector (Non-replicating) + APC LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene 1 Day 0 SC & IV Shenzhen Geno-Immune Medical Institute Phase 1/2
SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens.

44 PS Protein subunit AdimrSC-2f (recombinant RBD +/- Aluminium) NR NR NR Adimmune Corporation Phase 1

45 DNA DNA based vaccine Covigenix VAX-001 - DNA vaccines + proteo-lipid vehicle (PLV) formulation 2 Day 0 + 14 IM Entos Pharmaceuticals Inc. Phase 1
46 DNA DNA based vaccine CORVax12 - Spike (S) Protein Plasmid DNA Vaccine 2 Day 0 + 14 ID OncoSec Immunotherapies; Providence Health & Services Phase 1
47 RNA RNA based vaccine ChulaCov19 mRNA vaccine 2 Day 0 + 21 IM Chulalongkorn University Phase 1
48 DNA DNA based vaccine bacTRL-Spike oral DNA vaccine 1 Day 0 Oral Symvivo Corporation Phase 1
49 VVnr Viral vector (Non-replicating) Human Adenovirus Type 5: hAd5 S+N bivalent vaccine (S-Fusion + N-ETSD). E2b- Deleted Adeno. 1-2 Day 0 + 21 SC or Oral or SL ImmunityBio, Inc Phase 1/2

50 VVnr Viral vector (Non-replicating) COH04S1 (MVA-SARS-2-S) - Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2 1-2 Day 0 + 28 IM City of Hope Medical Center + National Cancer Institute Phase 1

51 VVr Viral vector (Replicating) rVSV-SARS-CoV-2-S Vaccine (IIBR-100) 1 Day 0 IM Israel Institute for Biological Research Phase 2/3
52 VVr + APC Viral vector (Replicating) + APC Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded 1 Day 0 IM Aivita Biomedical, Inc; Phase 2
with antigens from SARS-CoV-2, with or without GM-CSF National Institute of Health Research and Development;
Ministry of Health Republic of Indonesia

53 LAV Live attenuated virus COVI-VAC 1-2 Day 0 or IN Codagenix/Serum Institute of India Phase 3
Day 0 + 28

54 PS Protein subunit CIGB-669 (RBD+AgnHB) 3 Day 0 + 14 + 28 or IN Center for Genetic Engineering and Biotechnology (CIGB) Phase 1/2
Day 0 +28 + 56
55 PS Protein subunit CIGB-66 (RBD+aluminium hydroxide)   3 Day 0 + 14 + 28 or IM Center for Genetic Engineering and Biotechnology (CIGB) Phase 3
Day 0 +28 + 56
56 IV Inactivated Virus VLA2001 2 Day 0 + 21 IM Valneva, National Institute for Health Research, United Kingdom Phase 3

57 PS Protein subunit BECOV2 2 Day 0 + 28 IM Biological E. Limited Phase 3

58 VVnr Viral vector (Non-replicating) AdCLD-CoV19 (adenovirus vector) 1 Day 0 IM Cellid Co., Ltd. Phase 1/2
59 DNA DNA based vaccine GLS-5310 2 Day 0 + 56 or ID GeneOne Life Science, Inc. Phase 1/2
Day 0 + 84
60 PS Protein subunit Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted (Nanocovax) 2 Day 0 + 21 IM Nanogen Pharmaceutical Biotechnology Phase 3

61 PS Protein subunit Recombinant protein vaccine S-268019 (using Baculovirus expression vector system) 2 Day 0 + 21 IM Shionogi Phase 1/2

Viral vector (Non-replicating) AdCOVID, Adenovirus-based platform expresses receptor-binding domain (RBD) of spike protein 1-2 Day 0 IN Altimmune, Inc. Phase 1
62 PS Protein subunit SARS-CoV-2-RBD-Fc fusion protein (AKS-452) 1-2 NR SC or IM University Medical Center Groningen + Akston Biosciences Inc. Phase 2
63 IV Inactivated Virus TURKOVAC, inactivated virus 2 Day 0 + 21 IM Erciyes University and the Health Institutes of Turkey (TUSEB) Phase 3

64 PS Protein subunit COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant 2 Day 0 + 28 IM University of Saskatchewan Phase 1/2

65 PS Protein subunit GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide) 2 Day 0 + 28 IM SK Bioscience Co., Ltd. and CEPI Phase 3

66 PS Protein subunit Razi Cov Pars, recombinant spike protein 3 Day 0 + 21 +51 IM and IN Razi Vaccine and Serum Research Institute Phase 3

67 IV Inactivated Virus COVID-19 inactivated vaccine, (CovIran-Barkat) 2 Day 0 + 14 IM Shifa Pharmed Industrial Co Phase 2/3

68 PS Protein subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine  2 Day 0 + 28 IM The University of Queensland Phase 1
68

69 DNA DNA based vaccine COVIGEN  2 Day 0 + 28 ID or IM University of Sydney, Bionet Co., Ltd Phase 1
Technovalia
70 DNA DNA based vaccine COVID-eVax, a candidate plasmid DNA vaccine of the Spike protein 2 Day 0 + 28 IM or Takis + Rottapharm Biotech Phase 1/2
IM + electroporation
71 VVnr Viral vector (Non-replicating) BBV154, Adenoviral vector COVID-19 vaccine 1 Day 0 IN Bharat Biotech International Limited Phase 1
72 RNA RNA based vaccine PTX-COVID19-B, mRNA vaccine 2 Day 0 + 28 IM Providence Therapeutics Phase 1
73 IV Inactivated virus Inactivated (NDV-based) chimeric vaccine with or without the adjuvant CpG 1018 2 Day 0 + 28 IM The Government Pharmaceutical Organization (GPO); PATH; Dynavax Phase 1/2

74 RNA RNA based vaccine CoV2 SAM (LNP) vaccine. A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen 2 Day 0 + 30 IM GlaxoSmithKline Phase 1

VBI-2902a. An enveloped virus-like particle (eVLP) of SARS-CoV-2 spike (S) glycoprotein and aluminum
75 VLP Virus like particle 2 Day 0 + 28 IM VBI Vaccines Inc. Phase 1/2
phosphate adjuvant.

76 PS Protein subunit SK SARS-CoV-2 recombinant surface antigen protein subunit (NBP2001) + adjuvanted with alum. 2 Day 0 + 28 IM SK Bioscience Co., Ltd. Phase 1
77 VVnr Viral vector (Non-replicating) Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying mRNA (SAM) vectors expressing spike 2-3 Day 0 + 14 + 28 or IM Gritstone Oncology 
alone, or spike plus additional SARS-CoV-2 T cell epitopes. Day 0 +28 + 56 or Phase 1
Day 0 + 112

78 RNA RNA based vaccine mRNA-1273.351. 3 Day 0 or Day 0 + 28 IM Moderna + National Institute of Allergy and Infectious Diseases (NIAID) Phase 4
A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion or Day 56
stabilized S protein of the SARS-CoV-2 B.1.351 variant.

79 PS Protein subunit 2-3 Day 0 + 28 + 180 IM Walter Reed Army Institute of Research (WRAIR) Phase 1
SpFN (spike ferritin nanoparticle) uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant.

80 PS Protein subunit EuCorVac-19; A spike protein using the recombinant protein technology and with an adjuvant. 2 Day 0 + 21 IM POP Biotechnologies and EuBiologics Co.,Ltd Phase 1/2
81 IV Inactivated virus Inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) 2 Day 0 + 14 +/- 21 IM Organization of Defensive Innovation and Research Phase 1

82 LAV Live attenuated virus MV-014-212, a live attenuated vaccine that expresses the spike (S) protein of SARS-CoV-2 1 Day 0 IN Meissa Vaccines, Inc. Phase 1
83 RNA RNA based vaccine MRT5500, an mRNA vaccine candidate 2 Day 0 + 21 IM Sanofi Pasteur and Translate Bio Phase 2
84 VLP Virus like particle SARS-CoV-2 VLP Vaccine 2 Day 0 SC The Scientific and Technological Research Council of Turkey Phase 2
Vaccine-Wuhan; Vaccine-Alpha variant; Vaccine-Wuhan+Alpha variant

85 PS Protein subunit ReCOV: Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell). 2 Day 0 + 21 IM Jiangsu Rec-Biotechnology Phase 2/3
86 RNA RNA based vaccine DS-5670a, mRNA vaccine 2 NR IM Daiichi Sankyo Co., Ltd. Phase 1/2
87 IV Inactivated Virus Koçak-19 Inactivated adjuvant COVID-19 viral vaccine 2 Day 0 + 21 IM Kocak Farma Phase 1

88 VVnr Viral vector (Non-replicating) COVIVAC. Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric 2 Day 0 + 28 IM Institute of Vaccines and Medical Biologicals, Vietnam Phase 1/2
SARS-CoV-2 S protein +/- adjuvant CpG 1018
89 VVnr Viral vector (Non-replicating) SC-Ad6-1, Adneviral vector vaccine 1-2 Day 0 +/- 21 IM Tetherex Pharmaceuticals Corporation Phase 2
90 VLP Virus like particle ABNCoV2 capsid virus-like particle (cVLP) +/- adjuvant MF59 2 Day 0 + 28 IM Radboud University Phase 1
91 PS Protein subunit Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) 2 Day 0 + 21 IM Livzon Pharmaceutical Phase 2

92 RNA RNA based vaccine HDT-301: Self-replicating mRNA vaccine formulated as a lipid nanoparticle. 2 Day 0 + 28 IM SENAI CIMATEC Phase 1
93 IV Inactivated Virus Adjuvanted inactivated vaccine against SARS-CoV-2 2 Day 0 + 21 SC The Scientific and Technological Research Council of Turkey (TÜBITAK) Phase 1
94 RNA RNA based vaccine mRNA-1283 2 Day 0 + 28 IM ModernaTX, Inc. Phase 1
mRNA-1283.211
95 PS Protein subunit Recombinant SARS-CoV-2 Vaccine (CHO cell) 2 Day 0 IM National Vaccine and Serum Institute, China; Beijing Zhong Sheng Heng Yi Phase 1/2
Pharmaceutical Technology; Lanzhou Institute of Biological Products

EXG-5003; a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of
96 RNA RNA based vaccine the SARS-CoV-2 spike protein. 1 Day 0 ID Elixirgen Therapeutics, Inc Phase 1/2
97 IV Inactivated Virus Inactivated COVID-19 vaccine 2 Day 0 + 28 IM KM Biologics Co., Ltd. Phase 2/3
98 IV Inactivated Virus Live recombinant Newcastle Disease Virus (rNDV) vector vaccine 2 Day 0 + 21 IM or IN Laboratorio Avi-Mex Phase 1
99 RNA RNA based vaccine mRNA COVID-19 vaccine 2 TBD IM Shanghai East Hospital and Stemirna Therapeutics Phase 1
100 PS Protein subunit CoVepiT vaccine: SARS-CoV-2 multi-target peptide vaccine (targeting Spike, M, N, and several non-structural 1-2 Day 0 +/- 21 SC OSE Immunotherapeutics Phase 1
101 VVnr Viral vector (Non-replicating) Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein 2 Day 0 + 28 IM German Center for Infection Research Phase 1/2
102 PS Protein subunit CoV2-OGEN1, protein-based vaccine 1-2 Day 0 +/- 14 Oral USSF/Vaxform Phase 1
103 PS Protein subunit QazCoVac-P - COVID-19 Subunit Vaccine 1-2 Day 0 + 21 IM Research Institute for Biological Safety Problems Phase 1/2

104 RNA RNA based vaccine LNP-nCOV saRNA-02 vaccine; Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP) 2 Day 0 + 28 IM MRC/UVRI and LSHTM Uganda Research Unit Phase 1
105 RNA RNA based vaccine mRNA-1273.211. A multivalent booster candidate combining mRNA-1273 plus mRNA-1273.351. 1 Day 0 IM ModernaTX, Inc. Phase 2/3
106 PS Protein subunit RBD protein recombinant SARS-CoV-2 vaccine 3 Day 0 + 21 + 35 IM Bagheiat-allah University of Medical Sciences/AmitisGen Phase 2
Baiya SARS-CoV-2 VAX1, a plant-based subunit vaccine
107 PS Protein subunit (RBD-Fc + adjuvant) 2 Day 0 + 21 IM Baiya Phytopharm Co., Ltd. Phase 1

108 PS Protein subunit SCB-2020S, an adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant) 2 Day 0 + 21 IM Clover Biopharmaceuticals AUS Pty Ltd Phase 2
109 VVnr Viral vector (Non-replicating) PIV5 vector that encodes the SARS-CoV-2 spike protein 1 Day 0 IN CyanVac LLC Phase 1
110 VVnr Viral vector (Non-replicating) AZD2816; adenoviral vector ChAdOx platform and based on the Beta (B.1.351) variant 2 Day 0 + 28 IM AstraZeneca + University of Oxford Phase 2/3
111 PS Protein subunit 202-CoV; SARS-CoV-2 spike trimer protein + adjuvant, CpG7909. 2 Day 0 + 28 IM Shanghai Zerun Biotechnology + Walvax Biotechnology + CEPI Phase 1
112 DNA DNA based vaccine AG0302-COVID19 2-3 Day 0 + 14 + 28 IM AnGes, Inc/Osaka University Phase 1/2
113 PS Protein subunit Recombinant protein RBD fusion dimer adjuvanted vaccine (COVID-19 Vaccine Hipra) 2 Day 0 + 21 IM Laboratorios Hipra, S.A. Phase 2

114 PS Protein subunit Versamune-CoV-2FC vaccine, recombinant S1 antigen 3 Day 0 + 28 NR Farmacore Biotecnologia Ltda Phase 1/2
115 RNA RNA based vaccine ARCT-154 mRNA Vaccine 2 Day 0 + 28 IM Arcturus Therapeutics, Inc. Phase 3
116 RNA RNA based vaccine ARCT-165 mRNA Vaccine 2 Day 0 + 29 IM Arcturus Therapeutics, Inc. Phase 1/2
117 RNA RNA based vaccine ARCT-021 mRNA Vaccine 2 Day 0 + 30 IM Arcturus Therapeutics, Inc. Phase 1/2
118 PS Protein subunit SII B.1.351 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.351 (Beta) variant vaccine 2 Day 0 + 21 IM Novavax Phase 1/2
119 PS Protein subunit SII Bivalent + Matrix-M1 adjuvant, a bivalent SII vaccine containing antigen for both the ancestral strain an 1 Day 0 IM Novavax Phase 1/2
120 PS Protein subunit SII B.1.617.2 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine 1-2 Day 0 +/- 21 IM Novavax Phase 1/2
AAV5-RBD-S vaccine (BCD-250), A recombinant Adenovirus-Associated viral Vector (AAV-5) encoding spike
121 VVnr Viral vector (Non-replicating)
protein 1 Day 0 IM Biocad Phase 1/2
122 PS Protein subunit SCTV01C. A Bivalent Recombinant Trimeric S Protein vaccine against SARS-CoV-2 Variants 1 Day 0 IM Sinocelltech Ltd. Phase 2/3

123 IV Inactivated Virus Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) 2 Day 0 + 14 IM Chumakov Federal Scientific Center for Research and Development of Phase 1/2
Immune-and-Biological Products
124 DNA DNA based vaccine Plasmid DNA vaccine SCOV1 + SCOV2. COVIDITY 2 Day 0 + 28 ID/IM Scancell Ltd Phase 1
125 BacAg-SpV Bacterial antigen-spore expression vector COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores 3 Day 0 + 14 + 28 Oral DreamTec Research Limited NA

126 DNA DNA based vaccine VB10.2129, a DNA plasmid vaccine, encoding the receptor binding domain (RBD) 1-2 Day 0 + 21 IM Vaccibody AS Phase 1/2

127 DNA DNA based vaccine VB10.2210, DNA plasmid vaccine, encodes multiple immunogenic and conserved T cell 1-2 Day 0 + 21 IM Phase 1/2
epitopes spanning multiple antigens across the SARS-CoV-2 genome. Vaccibody AS
128 PS Protein subunit SARS-CoV-2 Protein Subunit Recombinant Vaccine 2 Day 0 + 28 IM Bio Farma Phase 1/2
129 PS Protein subunit PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine 2 Day 0 + 7 IM Yisheng Biopharma Phase 1
130 DNA DNA based vaccine SARS-CoV-2 DNA vaccine (delivered IM followed by electroporation) 2 Day 0 + 21 IM The University of Hong Kong; Immuno Cure 3 Limited Phase 1
Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines expressing SARS-CoV-
131 VVnr Viral vector (Non-replicating) 1 Day 0 AE McMaster University Phase 1
2 spike, nucleocapsid and RNA polymerase proteins
132 PS Protein subunit PepGNP-SARSCoV2, A CD8 T-cell priming adaptive vaccine composed of a Coronaviruses specific peptides 2 Day 0 + 21 ID Emergex Vaccines Holding Limited Phase 1
mounted on a gold nanoparticle
133 PS Protein subunit SARS-CoV-2 Vaccine (IN-B009) 2 Day 0 + 21 IM HK inno.N Corporation Phase 1
SARS-CoV-2 Vaccine LYB001, a receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle
134 VLP Virus like particle 3 Day 0 + 28 + 56 IM Yantai Patronus Biotech Co., Ltd. Phase 1
(VLP) vector, adjuvanted with aluminum hydroxide.
135 IV Inactivated Virus Covi Vax, inactivated coronavirus vaccine 2 Day 0 + 28 IM National Research Centre, Egypt Phase 1
136 RNA RNA based vaccine HDT-301 vaccine 1-2 Day 0 +/- 56 IM HDT Bio Phase 1
137 RNA RNA based vaccine VLPCOV-01, self-amplifying RNA vaccine against the coronavirus 2 NR IM VLP Therapeutics Japan GK Phase 1
 Current status of clinical evaluation (Trial registries and public reports) Phase 3 endpoints as per protocol
Number of virologically Efficacy compared to placebo Efficacy against severe and Efficacy for the prevention of
confirmed (PCR or NAAT
Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 Phase not reported positive) symptomatic cases of for theCoV-2
prevention of SARS- non-severe COVID-19: hospital COVID-19-related Emergency
infection admissions Department visits
COVID-19

NCT04383574 NCT04800133 NCT04456595 NCT04756830** ChiCTR2100045109 X X

Study Report NCT04884685 Study Report NCT04747821** NCT04771559
Study Report NCT04979949 Study Protocol NCT04775069
Study Report NCT04508075 NCT04789356 X X
NCT04352608 Study Report NCT04754698
Study Report Study Report
Study Report NCT05087368  NCT04582344 NCT04801888 X X X
Study Report Study report Study Report
NCT04551547 NCT05150496 NCT04617483 NCT04894227
Study Report NCT04651790 NCT04892459 X X X
NCT04992182 Study Report NCT05079217
Study Report NCT04911790
NCT04992260 NCT04953325 X X X
NCT05077176 NCT04962308 X
NCT04993365
NCT05137418 NCT05057169
NCT05107557
NCT05142319 NCT05112913
NCT05165732
NCT05148949
ChiCTR2000031809 IRCT20210113050024N3 NCT04885764 ChiCTR2000034780 NCT05065892 X X
Study Report ChiCTR2000039000 NCT05075044 X X
NCT04510207 NCT05075057 X
Study Report NCT05104437
Interim Report NCT04612972 X X
ChiCTR2000032459 NCT04998240 NCT04560881 NCT04863638 ChiCTR2100041704  X X
TCTR20210920005 NCT04917523 NCT05065879 ChiCTR2100041705
NCT05172193 NCT05075070 Study Report
Study Report NCT04510207 NCT05075083 ChiCTR2100041706 X X
NCT05162482 NCT04984408 NCT05104333 ChiCTR2100048665 
NCT05105295
NCT05104216 IRCT20210206050259N4
PACTR202005681895696 PACTR202006922165132 NCT04686773 NCT04400838 ISRCTN89951424 NCT04760132 NCT04794946** X
2020-001072-15 TCTR20211004005 Study Report NCT04516746 NCT04775069 NCT04939402 X X X
Interim Report ISRCTN69254139 Study Report NCT04540393 EUCTR2021-002327-38-NL NCT05074368
NCT04568031 Study Report Study Report NCT04536051 NCT04914832 X X
Study Report Study Report Study Report EUCTR2020-005226-28-DE ACTRN12621000661875 X X X
Study Report NCT04800133 Study Report Study Report NCT05132855
NCT04444674 NCT04860739** Study Report NCT05057897
Study Report Study Report
NCT04324606 Study Report CTRI/2020/08/027170 Study Report NCT05142488
Study Report NCT04894435 Study Report
Study Report ISRCTN73765130 ** Study Report NCT04864561
Study Report NCT04907331 NCT04885764 TCTR20211102003
Study Report NCT04998240 NCT05059106
NCT04684446 NCT05049226 TCTR20210720002 NCT05142319
NCT04760730 NCT05054621
ISRCTN15638344 IRCT20210113050024N3
TCTR20211102006 NCT05087368
NCT05162482
NCT05133609 ISRCTN27841311
NCT04816019 Study Report
 ChiCTR2000030906 ChiCTR2000031781 NCT04954092 NCT04526990 NCT04892459 NCT04916886 X X
NCT04313127 NCT04398147 NCT04566770 NCT04540419 Study Report NCT04952727 X X X
Study Report NCT05169008
NCT04568811 NCT04840992 NCT04341389
NCT04552366 NCT05043259 NCT05162482
Study Report Study Report
Study Report NCT05005156
NCT05124561 X X X
NCT05169008
NCT04436471 NCT04962906 NCT04530396 X X
NCT05027672 Study Report
NCT04437875 NCT04564716 X X
NCT04713488 NCT04587219 NCT04642339 X X
Study Report NCT04962906 NCT04640233 NCT04656613 X
NCT04760730 NCT04983537 NCT04741061 X X
NCT04988048
NCT04509947 NCT04436276 EUCTR2020-002584-63-DE NCT04505722 EUCTR2021-002327-38-NL NCT04817657 X X X
NCT04894305 Study Report NCT04535453 Study Report NCT04927936
Study Report NCT05030974 Study Report
Study Report NCT04765384 NCT04614948 NCT05081271 X X
Study Report NCT04838795 NCT05037266 X X
NCT04889209 NCT05048940 NCT05075538 X X X
NCT05047640 X X
NCT05109559 NCT05091307 X
NCT05142319
NCT04368988  NCT04533399 NCT04611802 X X
NCT05112848 Study Report
NCT04961541 Study Report Study Report EUCTR2020-004123-16-GB X X
Study Report ISRCTN73765130**  NCT04583995 X X X
Study Report Study Report
ISRCTN27841311
Study Report
NCT04283461 NCT04677660 NCT04405076** NCT04649151 NCT04470427 NCT04760132 NCT04900467 X X
Study Report Study Report NCT05060991 NCT05069636
Interim Report NCT04712110 Study Report Study report Study Report NCT04792567 NCT04927936
NCT04889209 NCT04811664 NCT04885907 NCT05074368 X
NCT04796896 Study Report
Study Report NL9275 NCT04761822 NCT04805125 EUCTR2021-002327-38-NL NCT05081271 X X X
Study Report NCT04894435 NCT05022329 NCT04806113 EUCTR2021-003388-90-NL
NCT04839315 ISRCTN73765130** NCT04860297 NCT04952402 NCT05132855
NCT04930770 NCT05048940 EUCTR2021-003618-37-NO X X X
NCT04969263 NCT04969250
NCT05077254 TCTR20211102003 NCT05030974
NCT05137236 NCT05119855 NCT05047718
ISRCTN27841311 NCT05142319 NCT05079633
Study Report NCT05075538
NCT05137236 NCT05075538
NCT04523571 2020-001038-36 NCT04649021 NCT04754594 NCT04368728** NCT04760132 NCT04844489** X X
EUCTR2021-005043-71-NL Study Report NCT05060991
Study Report ACTRN12621000661875
Study Report NCT04588480 NCT04761822 NCT05022329 Study Report EUCTR2021-000412-28-BE NCT04842708**
ChiCTR2000034825  NCT04380701 NCT04824638** Study Report EUCTR2021-002327-38-NL NCT04862806
Study Report Study Report NCT04860739 NCT04713553 NCT04780659 NCT04880174
Study Report NCT04961229
NCT04816643 NCT04537949 EUCTR2021-001978-37-ES NCT04800133 NCT04775069 NCT04900467
EUCTR2020-003267-26-DE NCT04894435 NCT04805125 EUCTR2021-000893-27-BE NCT04927936 X X
NCT04839315 Study Report ISRCTN73765130** NCT04816669 EUCTR2021-000930-32-BE NCT04961502
NCT04936997 NCT04889209 NCT04895982 NCT04951323 NCT04852861** IRCT20210708051820N1
NCT04969601 NCT04907331 NCT05142319 NCT04878211
NCT04949490 EUCTR2021-003388-90-NL NCT05075499
EUCTR2020-005442-42-PL TCTR20211102006 NCT04969263 NCT05047640 EUCTR2021-003618-37-NO X X
NCT05049226 NCT04955626 NCT05081271
ISRCTN27841311 TCTR20211102003 NCT04952766
Study Report NCT05124171 NCT04969250 ACTRN12621001465842
EUCTR2021-002348-57-AT NCT05047718
Study Report NCT05057169 NCT05135585
NCT05077254 NCT05057182 NCT05132855
TCTR20211027002 NCT05075538
NCT04445194  NCT04550351 NCT04466085 ChiCTR2100050849

Study Report NCT05091411

ChiCTR2000035691  Study Report NCT04646590 X X
  NCT04636333 NCT04813562 Study Report
NCT04961359 NCT05109598 NCT05128643
NCT04449276  NCT04515147 NCT04652102** NCT04674189 X X
Study Report PER-054-20 Study report NCT04838847 X
ISRCTN73765130** NCT04860258
NCT04470609 NCT04659239 NCT04944381 X X
NCT04412538 NCT05163652
Study Report NCT05033847
Study Report NCT05164731
NCT04530357 NCT04691908 X X
Study Report

NCT04336410 NCT04447781 ChiCTR2000040146  NCT04642638 ISRCTN15779782 X X

Study Report Study report
ChiCTR2000038152 
NCT04463472 NCT04655625 X X
NCT04527081
jRCT2051200085
CTRI/2020/07/026352 CTRI/2020/07/026352 X X
CTRI/2021/03/032051
NCT04445389 NCT05067946
NCT04715997
X X
NCT04471519 NCT04918797 NCT04641481; CTRI/2020/11/028976

Interim Study Report Study Report

Study Report
Study Report
Study report
CTRI/2020/07/026300
CTRI/2020/09/027674
NCT04473690
NCT04537208 NCT04762680 PACTR202011523101903* X X
NCT05124171
Study Report STudy Report
X X X
NCT04904549
NCT04480957 NCT04668339
NCT04728347
ACTRN12620000817943
ACTRN12620001308987
NCT04758273 NCT04756323 NCT04852705 X
Study Report Study Report
NCT05003479 NCT05003466
NCT04528641 NCT04791423 X X X

NCT04563702 NCT05067933

NCT04569383
NCT04405908 NCT04954131 NCT04672395 NCT05012787 X X
Study Report NCT05087368
Report
NCT04932824
NCT04453852 IRCT20150303021315N23 NCT05005559 IRCT20150303021315N24
NCT04944368 NCT05148871
NCT04806529
Development has been suspended and the candidate vaccine has been removed from the landscape summary analysis
NCT04487210 NCT04695652
NCT05011526 NCT05079633 X
Study Report NCT05097053 X
NCT04822025 ISRCTN15779782 X X X
NCT04951388 NCT05132855
NCT05038618
NCT05048849
NCT05054621
RPCEC00000338 RPCEC00000332 RPCEC00000366
RPCEC00000391
RPCEC00000340 RPCEC00000347 RPCEC00000354 X X
Study Report
NCT04527575 NCT04780035
X X X X
Study Report
ChiCTR2000037518 NCT05013983 ChiCTR2000039994 NCT04887207 X X
NCT04530656 NCT04640402 NCT04904471 X X X
Study Report
 Study Report NCT04718467
NCT04546841 NCT04954469
NCT04545749 NCT04773067 NCT04683224 X X
NCT04967742

NCT04497298 CT04498247
Development has been suspended and the candidate vaccine has been removed from the landscape summary analysis
NCT04569786

ChiCTR2000037782 ChiCTR2000039715 ChiCTR2100051391 X X

NCT04809389
ISRCTN17072692
ChiCTR2000034112 ChiCTR2100041855  NCT04847102
X
ChiCTR2000039212 
NCT04450004 NCT05065619 NCT04662697 NCT04636697 X X
Study Report Study report NCT05040789
Study Report Study report
NCT04299724

NCT04276896

NCT04522089 NCT05104489
NCT04591184
NCT04627675
NCT04566276
NCT04334980
NCT04591717 NCT04843722

NCT04710303 NCT04845191
NCT04732468 NCT04843722
NCT04639466 NCT04977024
Pre-clinical result
NCT04608305 NCT04990466
NCT04690387 NCT04386252 NCT05007496

NCT04685603
NCT04619628 ISRCTN15779782 X X X

RPCEC00000345
RPCEC00000346 RPCEC00000359 X X X
Study Report
NCT04671017 ISRCTN73765130** NCT04864561
Study Report NCT04956224
Study Report
CTRI/2020/11/029032 CTRI/2021/08/036074
NCT05047692 NCT04666012
NCT05085639 NCT04673149

NCT04683484 NCT04922788 X X
Study Report

jRCT2051200092

NCT04679909 Altimmune have discontinued further development of AdCOVID, therefore the candidate vaccine has been removed from the landscape summary analysis
NCT04681092 NCT05124483
NCT04691947  NCT04824391 NCT04942405 X
NCT05035238 NCT05077176 X
NCT04979949
NCT04702178

NCT05155982 NCT04742738 NCT05007951

NCT04750343
NCT05175950
IRCT20201214049709N1 IRCT20201214049709N2 IRCT20210206050259N3 IRCT20201214049709N4 X
IRCT20201214049709N3
IRCT20201202049567N1 IRCT20171122037571N3 IRCT20201202049567N3 X X
IRCT20201202049567N2
NCT04495933
Study Report
 Study Report

NCT04742842

NCT04788459
EUCTR2020-003734-20-IT
NCT04751682
NCT04765436
NCT04764422
Study Report

NCT04758962

NCT04773665

NCT04760743

NCT04776317

NCT04785144 NCT04847050 EUCTR2021-000930-32

NCT04878211
NCT04869358
NCT04784767

NCT04783311
IRCT20210206050259N1 IRCT20210206050259N2 IRCT20210206050259N4

NCT04798001
NCT04798027
NCT04818281 NCT04962893

NCT04818801 NCT05084989

NCT04821674
NCT04838080

NCT04830800

NCT04839042 NCT05077267
NCT04839146
ChiCTR2100045108 ChiCTR2100045107 NCT05096832 NCT05125874 X X X
NCT05050474 NCT05096845 X X X
NCT04844268
NCT04866069
NCT04813796 NCT05137236
NCT05137236
NCT04869592

NCT05069129

NCT04863131

jRCT2071200106 jRCT2071210081
NCT04871737
ChiCTR2100045984 NCT05144139 NCT04944381
NCT04885361
NCT04895449
NCT04893512
NCT04930003

NCT04934111

NCT04927065
IRCT20210620051639N1 IRCT20210620051639N2

NCT04953078

NCT04950751 **
NCT04954287
NCT04973449
NCT04982068 NCT04990544
NCT04993586
NCT05007509 EUCTR2021-005226-26-ES
NCT05142514
NCT05142553
NCT05016934
 NCT05037097 NCT05012943 ISRCTN15779782 X X X
NCT05037097
NCT05037097
NCT05029856
NCT05029857
NCT05029858

NCT05037188

NCT05148091 NCT05043311
NCT05043285

NCT05046548

NCT05047445
NCT05057923
Study Report
NCT05069623

NCT05069623

NCT05067894
ACTRN12621001009808
NCT05102643

NCT05094609
NCT05113862

NCT05113849

NCT05125926 NCT05137444

NCT05128721
NCT05132907
jRCT2071210067
Phase 3 endpoints as per protocol
Efficacy of vaccine against Efficacy of vaccine against Assess humoral Safety and immunogenicity of
severe and non-severe COVID- severe and non-severe COVID- Efficacy: seroconversion rates immunogenicity : antibody a booster dose
19 19: number of deaths quantification

X X X X

X X X X X

X X X X X

X X X
X X X X X

X X X X X
X X X

X X X

X X X

X X X
X X X X X
X X X

X X X X
X X X X
X X

X X X X X

X X X X X
X X X
X X X
X X X X
X X X X

X X X
X X
X X X
X X X X
X X X

X X X
X X X
X X X

X X X
X X X
X X X
X X

X X X X

X X X X
X X X X X
X X X
X X X X
X X X
X X X
X X X X

X X X
X X X

X X X X

X X X

X X X X X
X X X

X X X

X X
X X
X X X

X X X X

X X

X X X
X X X X
X X X
X X X
X X X

X X X X

X X
X X

X X
X X X X
 X X
X X X X
X X X
X X X
X X X
X X X
X X X X X
X X X
X X X

X X X X X

X X X

X X X

X X X X

X X X
X X
X X X X

X X X X X

X X X X X

X X X X

X X
X X X
X X X X

X X X X X

X X X X X

X X X X X
X X X X X
X X X X

X X X

X X X

X X X X
X X

X X X X

X X X X X

X X X
X X X

X X X

X X X X X

X X
X X X

X X X

X X X X X

X X X X X
X X X X X
X X X X X
X X X X
Landscape of candidate vaccines in pre-clinical development
DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does
not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).  While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO
does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes),  quality, safety, efficacy, merchantability and/or non-infringement of any information
provided in these landscape documents and/or of any of the products referenced therein.  WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with
the procurement, distribution or use of any product included in any of these landscape documents.

New information that has been added this week.

The vaccine candidates listed here are currently in the pre-clinical phase of research and development. When the vaccine progresses from pre-clinical to clinical phase and the study of the vaccine is registered in a clinical trial database that can be publicly accessed, it will then appear in the clinical list of the WHO landscap

Vaccine Same platform for non-

ID platform Vaccine platform description Type of candidate vaccine Coronavirus target Coronavirus candidates
acronym
SARS-CoV-2 and Sarbeco-
1 DNA DNA based vaccine DNA, engineered vaccine inserts compatible with multiple delivery systems CoV
2 DNA DNA based vaccine DNA vaccine SARS-CoV2
3 DNA DNA based vaccine DNA plasmid vaccine RBD&N SARS-CoV2
4 DNA DNA based vaccine DNA with electroporation SARS-CoV2
5 DNA DNA based vaccine DNA with electroporation SARS-CoV2
6 DNA DNA based vaccine Plasmid DNA, Needle-Free Delivery SARS-CoV2 SARS
7 DNA DNA based vaccine DNA plasmid vaccine S,S1,S2,RBD &N SARS-CoV2
8 DNA DNA based vaccine DNA vaccine SARS-CoV2
9 DNA DNA based vaccine msDNA vaccine SARS-CoV2
10 DNA DNA based vaccine DNA vaccine SARS-CoV2
11 DNA DNA based vaccine DNA plasmids containing S-gene SARS-CoV2
12 DNA DNA based vaccine DNA plasmid vaccine SARS-CoV2
13 DNA DNA based vaccine Plasmid DNA, nanostructured RBD SARS-CoV2
14 DNA DNA based vaccine DNA plasmid  vaccine encoding RBD SARS-CoV2
15 DNA DNA based vaccine DNA Immunostimulatory sequences SARS-CoV2
The 3 regions of SARS-Cov-2 Spike-protein: NTD, RBD and HR1-HR2 inserted into the
16 DNA DNA based vaccine plasmid of PcDNA3.1 (+). SARS-CoV2

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing

17 IV Inactivated virus membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + SARS-CoV-2
CpG 1018
18 IV Inactivated virus Inactivated + alum SARS-CoV2 JE, Zika
19 IV Inactivated virus Inactivated SARS-CoV2
20 IV Inactivated virus SARS-CoV2
21 IV Inactivated virus Inactivated + CpG 1018 SARS-CoV2
22 IV Inactivated virus Inactivated + CpG 1018 SARS-CoV2
23 IV Inactivated virus Inactivated whole virus SARS-CoV2
24 IV Inactivated virus Inactivated SARS-CoV2 MMR, IPV
25 IV Inactivated virus Inactivated SARS-CoV2 MMR, IPV
26 IV Inactivated virus Inactivated + alum SARS-CoV2
27 IV Inactivated virus Inactivated vaccine (Vero Cell) SARS-CoV2
LAV Live attenuated virus Codon deoptimized live attenuated vaccines SARS-CoV2
28
29 LAV Live attenuated virus Codon deoptimized live attenuated vaccines SARS-CoV2
30 LABV Live attenuated bacterial vector Live attenuated bacterial (Pertussis) Vector SARS-CoV2
31 LABV Live attenuated bacterial vector Live attenuated bacterial vector SARS-CoV2
32 VVnr Viral vector (Non-replicating) Sendai virus vector SARS-CoV2
33 VVnr Viral vector (Non-replicating) Sendai virus vector SARS-CoV2 RSV, CMV
34 VVnr Viral vector (Non-replicating) Adenovirus-based SARS-CoV2
35 VVnr Viral vector (Non-replicating) Adeno-associated virus vector (AAVCOVID) SARS-CoV2
36 VVnr Viral vector (Non-replicating) MVA encoded VLP SARS-CoV2 LASV, EBOV, MARV, HIV
37 VVnr Viral vector (Non-replicating) MVA-S SARS-CoV2
38 VVnr Viral vector (Non-replicating) Adeno5-based SARS-CoV2  
39 VVnr Viral vector (Non-replicating) Ad5 S (GREVAX™ platform) SARS-CoV2 MERS
40 VVnr Viral vector (Non-replicating) Oral Ad5 S SARS-CoV2 Zika, VZV, HSV-2 and Norovirus
41 VVnr Viral vector (Non-replicating) Adenovirus-based + HLA-matched peptides Pan-Corona
42 VVnr Viral vector (Non-replicating) MVA expressing structural proteins SARS-CoV2 Multiple candidates
43 VVnr Viral vector (Non-replicating) Parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein SARS-CoV2 MERS
HeV, NiV, EBOV, LASSA, CCHFV,
44 VVnr Viral vector (Non-replicating) Recombinant deactivated rabies virus containing S1 SARS-CoV2 MERS
45 VVnr Viral vector (Non-replicating) Influenza A H1N1 vector SARS-CoV2
46 VVnr Viral vector (Non-replicating) Newcastle disease virus expressing the spike protein SARS-CoV2
47 VVnr Viral vector (Non-replicating) Newcastle disease virus expressing membrane-anchored spike SARS-CoV2
48 VVnr Viral vector (Non-replicating) Lentiviral Vector SARS-CoV2
49 VVnr Viral vector (Non-replicating) Lentiviral Vector SARS-CoV2
50 VVnr Viral vector (Non-replicating) Lentiviral Vector Retro-VLP Particles SARS-CoV2
51 VVnr Viral vector (Non-replicating) Ad 5 vector for intranasal administration SARS-CoV2
InfA, CHIKV, LASV, NORV; EBOV,
52 VVnr Viral vector (Non-replicating) Oral vaccine platform SARS-CoV2 RVF, HBV, VEE
53 VVnr Viral vector (Non-replicating) Recombinant Adenovirus Vector (Type 5) + Spike protein of SARS-CoV-2 SARS-CoV2
54 VVnr Viral vector (Non-replicating) Recombinant Adenovirus Vector (ChAdOx1) + Spike protein of SARS-CoV-2 SARS-CoV2
55 VVnr Viral vector (Non-replicating) Adenovirus-based SARS-CoV2
56 VVnr Viral vector (Non-replicating) Chimpanzee adenovirus vector expressing the RBD-dimer without adjuvant SARS-CoV2
57 PS Protein subunit RBD protein delivered in mannose-conjugated chitosan nanoparticle SARS-CoV2
58 PS Protein subunit Recombinant spike protein with Essai O/W 1849101 adjuvant SARS-CoV2
59 PS Protein subunit Peptides SARS-CoV2
60 PS Protein subunit Recombinant spike protein with Essai O/W 1849101 adjuvant SARS-CoV2
61 PS Protein subunit Recombinant S protein SARS-CoV2
62 PS Protein subunit RBD protein (baculovirus production) + FAR-Squalene adjuvant SARS-CoV2 Multiple candidates
63 PS Protein subunit RBD-protein SARS-CoV2
64 PS Protein subunit Recombinant S protein SARS-CoV2
65 PS Protein subunit Peptide + novel adjuvant SARS-CoV2
66 PS Protein subunit S subunit intranasal liposomal formulation with GLA/3M052 adjs. SARS-CoV2
67 PS Protein subunit S-Protein (Subunit) + Adjuvant, E coli and Insect vectors for expression/synthesis of the SARS-CoV2
protein
68 PS Protein subunit Protein Subunit S,N,M&S1 protein SARS-CoV2
69 PS Protein subunit Protein Subunit SARS-CoV2
70 PS Protein subunit RBD protein fused with Fc of IgG + Adj. SARS-CoV2
71 PS Protein subunit Capsid-like Particle SARS-CoV2
72 PS Protein subunit Drosophila S2 insect cell expression system VLPs SARS-CoV2
73 PS Protein subunit Peptide antigens formulated in LNP SARS-CoV2
74 PS Protein subunit S protein SARS-CoV2
75 PS Protein subunit S protein +Adjuvant SARS-CoV2 Influenza
76 PS Protein subunit VLP-recombinant protein + Adjuvant SARS-CoV2
77 PS Protein subunit microneedle arrays S1 subunit SARS-CoV2 MERS
78 PS Protein subunit Peptide SARS-CoV2
79 PS Protein subunit Adjuvanted protein subunit (RBD) SARS-CoV2
Ebola, Marburg, HIV, Zika,
80 PS Protein subunit Peptide SARS-CoV2 Influenza, HPV therapeutic
vaccine, BreastCA vaccine
81 PS Protein subunit S protein SARS-CoV2
82 PS Protein subunit Ii-Key peptide SARS-CoV2 Influenza, HIV, SARS-CoV
83 PS Protein subunit S protein SARS-CoV2 H7N9
84 PS Protein subunit Protein Subunit EPV-CoV-19 SARS-CoV2
85 PS Protein subunit gp-96 backbone SARS-CoV2 NSCLC, HIV, Malaria, Zika
86 PS Protein subunit Subunit vaccine SARS-CoV2
87 PS Protein subunit S1 or RBD protein SARS-CoV2 SARS
88 PS Protein subunit Subunit protein, plant produced SARS-CoV2

89 PS Protein subunit Recombinant protein, nanoparticles (based on S-protein and other epitopes) SARS-CoV2

Cross-reactive T-cell recombinant vaccine based on SARS-CoV-2 nucleoprotein (N)

90 PS Protein subunit expressed in E.coli SARS-CoV2 various (cross-immunity)

91 PS Protein subunit COVID-19 XWG-03 truncated S (spike) proteins SARS-CoV2 HPV

92 PS Protein subunit Adjuvanted microsphere peptide SARS-CoV2
93 PS Protein subunit Synthetic Long Peptide Vaccine candidate for S and M proteins SARS-CoV2
94 PS Protein subunit Oral E. coli-based protein expression system of S and N proteins SARS-CoV2
95 PS Protein subunit Nanoparticle vaccine SARS-CoV2
96 PS Protein subunit Plant-based subunit (RBD-Fc + Adjuvant) SARS-CoV2
97 PS Protein subunit OMV-based vaccine SARS-CoV2 Flu A, Plague
98 PS Protein subunit OMV-based vaccine SARS-CoV2
99 PS Protein subunit structurally modified spherical particles of the tobacco mosaic virus (TMV) SARS-CoV2 Rubella, Rotavirus
100 PS Protein subunit Spike-based SARS-CoV2 Hepatitis C
101 PS Protein subunit Recombinant S1-Fc fusion protein SARS-CoV2
102 PS Protein subunit Recombinant protein SARS-CoV2
103 PS Protein subunit Recombinant S protein in IC-BEVS (Viral vector vaccine SARS-CoV2
(based on baculovirus expression system in insect cell line)
104 PS Protein subunit Orally delivered, heat stable subunit SARS-CoV2
105 PS Protein subunit Peptides derived from Spike protein SARS-CoV2
106 PS Protein subunit Protein Subunit SARS-CoV2
107 PS Protein subunit RBD-based SARS-CoV2
108 PS Protein subunit Outer Membrane Vesicle (OMV)-subunit SARS-CoV2
109 PS Protein subunit Spike-based (epitope screening) SARS-CoV2
110 PS Protein subunit Spiked-based SARS-CoV2
111 PS Protein subunit Recombinant spike with adjuvant SARS-CoV2
112 PS Protein subunit Recombinant S protein produced in BEVS SARS-CoV2
113 PS Protein subunit Protein Subunit Nanoformulated SARS-CoV2
114 PS Protein subunit Protein Subunit Adenoviral Carrier SARS-CoV2
115 PS Protein subunit Protein DC-targeted epitopes SARS-CoV2
116 PS Protein subunit Soluble recombinant S protein produced in CHO cells SARS-CoV2
NYVAC-KC, attenuated vaccinia virus vector expressing SARS-CoV-2 Spike and other
117 PS Protein subunit viral proteins SARS-CoV2
118 PS Protein subunit Protein peptides with alum SARS-CoV2
119 PS Protein subunit Recombinant Spike (S) proteins encoded by Baculoviruses in Insect cells SARS-CoV2
120 PS Protein subunit Adjuvanted Peptides + Recombinant Spike Protein SARS-CoV2
Development of recombinant protein based S1 and S2 (Spike) and nucleocapsid
121 PS Protein subunit subunits vaccines using a plant expression vector. SARS-CoV2

122 PS Protein subunit Recombinant Protein Vaccine

SARS-CoV2
123 PS Protein subunit Recombinant protein subunit vaccine SARS-CoV2
124 PS Protein subunit Recombinant Spike Protein SARS-CoV2
125 PS Protein subunit Recombinant SARS CoV-2 RBD Protein, Alum adjuvanted SARS-CoV2
126 PS Protein subunit TerraCoV2 recombinant protein (stabilized pre-fusion spike protein) Wuhan B.1.351 (Beta)
127 PS Protein subunit Multiple peptides fragments targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins to SARS-CoV2
induce T cell responses (CD8)
128 PS Protein subunit BD-COV-001 B.1.351 antigen encapsulated in polymersomes SARS-CoV2
129 PS Protein subunit Recombinant protein SARS-CoV2
130 PS Protein subunit Recombinant protein with hepatitis B VLP vector + Alum SARS-CoV3
131 PS Protein subunit Recombinant Protein (Leishmania host) SARS-CoV4
132 BVr Bacterial vector (Replicating) Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD SARS-CoV2 Multiple candidates
133 VVr Viral vector (Replicating) YF17D Vector SARS-CoV2
134 VVr Viral vector (Replicating) Measles Vector SARS-CoV2
135 VVr Viral vector (Replicating) Measles Vector SARS-CoV2
136 VVr Viral vector (Replicating) Measles Virus (S, N targets) SARS-CoV2 Zika, H7N9, CHIKV
137 VVr Viral vector (Replicating) Horsepox vector expressing S protein SARS-CoV2 Smallpox, Monkeypox
138 VVr Viral vector (Replicating) Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal) SARS-CoV2 Influenza

139 VVr Viral vector (Replicating) Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 SARS-CoV2 Influenza
(intranasal)
140 VVr Viral vector (Replicating) Attenuated Influenza expressing an antigenic portion of the Spike protein SARS-CoV2 Influenza
141 VVr Viral vector (Replicating) Influenza vector expressing RBD SARS-CoV2
Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-
142 VVr Viral vector (Replicating) CoV-2 Spike (S) glycoprotein. SARS-CoV2 Ebola, Marburg, Lassa
143 VVr Viral vector (Replicating) Replicating VSV vector-based DC-targeting SARS-CoV2
144 VVr Viral vector (Replicating) VSV-S SARS-CoV2 HIV, MERS
145 VVr Viral vector (Replicating) VSV-S SARS-CoV2
146 VVr Viral vector (Replicating) VSV vector SARS-CoV2
147 VVr Viral vector (Replicating) M2-deficient single replication (M2SR) influenza vector SARS-CoV2 Influenza
148 VVr Viral vector (Replicating) Newcastle disease virus vector (NDV-SARS-CoV-2/Spike) SARS-CoV2
149 VVr Viral vector (Replicating) Avian paramyxovirus vector (APMV) SARS-CoV2
150 VVr Viral vector (Replicating) Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing RBD protein: SARS-CoV2 Multiple candidates
rNDV-LS1-HN-RBD/SARS-CoV-2

151 Viral vector (Replicating)

Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing S1 protein: SARS-CoV2 Multiple candidates
VVr rNDV-LS1-S1-F/SARS-CoV-2
152 RNA RNA based vaccine saRNA formulated in a NLC SARS-CoV2
153 RNA RNA based vaccine LNP-encapsulated mRNA encoding S SARS-CoV2
154 RNA RNA based vaccine Self-amplifying RNA SARS-CoV2
155 RNA RNA based vaccine mRNA SARS-CoV2
156 RNA RNA based vaccine LNP-mRNA SARS-CoV2
157 RNA RNA based vaccine LNP-mRNA SARS-CoV2
158 RNA RNA based vaccine LNP-encapsulated mRNA cocktail encoding VLP SARS-CoV2
159 RNA RNA based vaccine LNP-encapsulated mRNA encoding RBD SARS-CoV2
160 RNA RNA based vaccine Replicating Defective SARS-CoV-2 derived RNAs SARS-CoV2
161 RNA RNA based vaccine LNP-encapsulated mRNA SARS-CoV2 MERS
162 RNA RNA based vaccine Liposome-encapsulated mRNA SARS-CoV2
163 RNA RNA based vaccine Several mRNA candidates SARS-CoV2
164 RNA RNA based vaccine mRNA SARS-CoV2
165 RNA RNA based vaccine mRNA SARS-CoV2
166 RNA RNA based vaccine mRNA in an intranasal delivery system SARS-CoV2
167 RNA RNA based vaccine mRNA SARS-CoV2
168 RNA RNA based vaccine mRNA SARS-CoV2
169 RNA RNA based vaccine mRNA SARS-CoV2
170 RNA RNA based vaccine mRNA SARS-CoV2
171 RNA RNA based vaccine mRNA SARS-CoV2
172 RNA RNA based vaccine D614G variant LNP-encapsulated mRNA SARS-CoV2
173 RNA RNA based vaccine Encapsulated mRNA SARS-CoV2
174 RNA RNA based vaccine Recombinant, prefusion stabilized SARS-CoV-2 Spike antigen SARS-CoV2
175 RNA RNA based vaccine ZIP1642 is a self-amplifying RNA vaccine encapsulated in an LNP, which encodes for SARS-CoV2
multiple antigens, including the Spike (S) protein.
176 VLP Virus like particle VLP SARS-CoV2
177 VLP Virus like particle Virus-like particle-based Dendritic Cell(DC)-targeting vaccine SARS-CoV2
178 VLP Virus like particle VLP SARS-CoV2
179 VLP Virus like particle Enveloped Virus-Like Particle (eVLP) SARS-CoV-2, SARS-CoV, & CMV, GBM, Zika
MERS-CoV

180 VLP Virus like particle S protein integrated in HIV VLPs SARS-CoV2

181 VLP Virus like particle VLP + Adjuvant SARS-CoV2

182 VLP Virus like particle Virus-like particles, lentivirus and baculovirus vehicles SARS-CoV2
183 VLP Virus like particle Virus-like particle, based on RBD displayed on virus-like particles SARS-CoV2
184 VLP Virus like particle ADDomerTM multiepitope display SARS-CoV2
185 VLP Virus like particle Unknown SARS-CoV2
186 VLP Virus like particle VLP SARS-CoV1, SARS-CoV2
187 VLP Virus like particle eVLP SARS-CoV2 Malaria
188 VLP Virus like particle VLPs peptides/whole virus SARS-CoV2
189 VLP Virus like particle VLPs produced in BEVS SARS-CoV2
190 VLP Virus like particle Plant derived VLP SARS-CoV2
191 VLP Virus like particle Myxoma virus co-expressing S, M, N and E proteins SARS-CoV2
192 VLP Virus like particle Plasmid driven production of virus -Like-Particles (VLPs) containing S, M, N and E SARS-CoV2
proteins of SARS-CoV-2
193 VLP Virus like particle Virus Like Particle with RCB SARS-CoV2
194 Cell Cellular based vaccine Engineered human mesenchymal stem cells transfected with a plasmid expressing S SARS-CoV2
and N-protein
 Friday, January 7, 2022
any particular product or entity in any of these landscape documents does
curacy of the information presented in these landscape documents, WHO
y, efficacy, merchantability and/or non-infringement of any information
age or other prejudice of any kind that may arise from or in connection with

ase that can be publicly accessed, it will then appear in the clinical list of the WHO landscape document.

Developers

DIOSynVax Ltd + University of Cambridge

Ege University
Scancell/University of Nottingham/ Nottingham Trent University
Karolinska Institute / Cobra Biologics (OPENCORONA Project)
Chula Vaccine Research Center
Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet
National Research Centre, Egypt
BioNet Asia
Mediphage Bioceuticals/University of Waterloo
Entos Pharmaceuticals
Biosun Pharmed
Globe Biotech Limited, Bangladesh
National institute of Chemistry, Slovenia
Vaccibody, Oslo Research Park, Norway
Inserm
Center of Genomics and Bioinformatics of Academy of Science of Republic of
Uzbekistan

Institute Butantan (Brazil) / Dynavax / PATH

KM Biologics
Selcuk University
Osaka University/ BIKEN/ NIBIOHN
Sinovac/Dynavax
Valneva/Dynavax
National Research Centre, Egypt
Milad Pharmaceutics Co.
Zista Kian Azma Co.
Paya Fan Yakhte Alborz - Osveh / Iran
Airlangga University, Indonesia in partnership with Biotis Pharmaceuticals
Indonesia
Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S.

Indian Immunologicals Ltd/Griffith University

Institut Pasteur Lille, Inserm
ALtraBio, TheRex
ID Pharma
Max Planck Institute for Biochemstry/vir4vac, Germany
Ankara University
Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis
GeoVax/BravoVax
IDIBAPS-Hospital Clinic, Spain
Erciyes University
Greffex
Stabilitech Biopharma Ltd
Valo Therapeutics Ltd
Centro Nacional Biotecnología (CNB-CSIC), Spain
University of Georgia/University of Iowa
Bharat Biotech/Thomas Jefferson University

National Research Centre, Egypt

Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
Theravectys – Institut Pasteur
AIOVA
Sorbonne University
University of Helsinki & University of Eastern Finland
Vaxart

Pasteur Institute / Iran

Pasteur Institute / Iran
Home Iman Zist Fanavar
Chengdu Kanghua Biological Products Co., Ltd.
Ohio State University / Kazakh National Agrarian University
Kazakh National Agrarian University
Neo7Logic
Kazakh National Agrarian University, Kazakhstan / National Scientific Center
for Especially Dangerous Infections
Max-Planck-Institute of Colloids and Interfaces
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)
Mynvax
Izmir Biomedicine and Genome Center
Bogazici University
University of Virginia
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory,
Ogbomoso, Oyo State, Nigeria.
National Research Centre, Egypt
University of San Martin and CONICET, Argentina
Chulalongkorn University/GPO, Thailand
AdaptVac (PREVENT-nCoV consortium)
ExpreS2ion
IMV Inc
WRAIR/USAMRIID
National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma
Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan
Univ. of Pittsburgh
Vaxil Bio
Biological E Ltd

Flow Pharma Inc

AJ Vaccines
Generex/EpiVax
EpiVax/Univ. of Georgia
EpiVax
Heat Biologics/Univ. Of Miami
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Baylor College of Medicine
iBio/CC-Pharming
Saint-Petersburg scientific research institute of vaccines and serums

FSUE SPbSRIVS FMBA of Russia (St. Petersburg Institute of Vaccines)

Innovax/Xiamen Univ./GSK
VIDO-InterVac, University of Saskatchewan
OncoGen
MIGAL Galilee Research Institute
LakePharma, Inc.
Baiya Phytopharm/ Chula Vaccine Research Center
Quadram Institute Biosciences
BiOMViS Srl/Univ. of Trento
Lomonosov Moscow State University
University of Alberta
AnyGo Technology
Yisheng Biopharma
Vabiotech, Vietnam and University of Bristol, UK
Applied Biotechnology Institute, Inc.
Axon Neuroscience SE
MOGAM Institute for Biomedical Research, GC Pharma
Neovii/Tel Aviv University
Intravacc/Epivax
ImmunoPrecise/LiteVax BV
Nanografi Nano Technology, Middle East Technical University, Ankara
University,
Iran
Tampere University
Vaxinano, CEA, INRAE
CEA, CNRS
LinkinVax, VRI, Inserm
Center for Advanced Technologies, Uzbekistan
Arizona State University

Hacettepe University, Turkey

Marmara University, Turkey
Yıldız Technical University, Turkey
Akdeniz University, Department of Agricultural Biotechnology, Antalya, Turkey
Ataturk University, Vaccine Research Center (Erzurum) and Health Institutes of
Turkey (TUSEB)
Pharmada Pharmaceuticals/TURKEY

CinnaGen Co
Bio Farma + Baylor College Medicine
Oragenics Inc, in cooperation with NRC Canada and Biodextris, Inc
OSE immunotherapeutics
ACM Biosciences
Biosun Pharmed / Iran
Rahpouyan Fanavar Sadegh (RFS) / Iran
Zist Salak / Iran
Farmacológicos Veterinarios SAC (FARVET SAC)
KU Leuven
Cadila Healthcare Limited
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
DZIF – German Center for Infection Research/CanVirex AG
Tonix Pharma/Southern Research
BiOCAD and IEM

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Fundação Oswaldo Cruz and Instituto Buntantan
University of Hong Kong
IAVI/Merck
University of Manitoba
University of Western Ontario
Aurobindo
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
UW–Madison/FluGen/Bharat Biotech
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.
The Lancaster University, UK
Farmacológicos Veterinarios SAC (FARVET SAC)

Farmacológicos Veterinarios SAC (FARVET SAC)

Infectious Disease Research Institute/ Amyris, Inc.
Max-Planck-Institute of Colloids and Interfaces
Gennova
Selcuk University
Translate Bio/Sanofi Pasteur
CanSino Biologics/Precision NanoSystems
Fudan University/ Shanghai JiaoTong University/RNACure Biopharma
Fudan University/ Shanghai JiaoTong University/RNACure Biopharma
Centro Nacional Biotecnología (CNB-CSIC), Spain
University of Tokyo/ Daiichi-Sankyo
BIOCAD
RNAimmune, Inc.
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
China CDC/Tongji University/Stermina
eTheRNA
Greenlight Biosciences
IDIBAPS-Hospital Clinic, Spain
Providence Therapeutics
Cell Tech Pharmed
ReNAP Co.
Globe Biotech Ltd
CEA
Medigen Vaccines Biologics Corp (MVC)/Vaxess Technologies (MIMIX)
Ziphius Vaccines and Ghent University
Max Planck Institute for Dynamics of Complex Technical Systems
University of Manitoba
Bezmialem Vakif University
VBI Vaccines Inc.

IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing

Centre/Grifols
Mahidol University/ The Government Pharmaceutical Organization
(GPO)/Siriraj Hospital
Navarrabiomed, Oncoimmunology group
Saiba GmbH
Imophoron Ltd and Bristol University’s Max Planck Centre
Doherty Institute
OSIVAX
ARTES Biotechnology
Univ. of Sao Paulo
Tampere University
Shiraz University
Arizona State University
Arizona State University
Berna Biotech Pharma
Cell Tech Pharmed